LOGIN OR REGISTER
Course Library

Optimizing the Use of DMD Therapy in MS Management

Neurology
Curriculum:
Optimizing the Use of DMD Therapy in MS Management
Credits:
1 AMA PRA Category 1 Credit(s) ™
Launch Date:
December 17, 2013
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Neurologists and other health care providers actively involved in the care of patients with multiple sclerosis

Relevant Terms:

Biomarkers, CIS, Clinically Isolated Syndrome, Disease-modifying Drug Therapy, DMD, Glatiramer Acetate, IFN, Interferon Beta, Interferons, Magnetic Resonance Imaging, MRI, MS, MS Diagnosis, Multiple Sclerosis, Radiologically Isolated Syndrome, RIS

Aaron E. Miller, MD

Aaron E. Miller, MD
Professor of Neurology and Medical Director
Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY

Aaron E. Miller, MD is Professor of Neurology at Mount Sinai School of Medicine and Medical Director at the Corinne Goldsmith Dickinson Center for Multiple Sclerosis. He is widely recognized for his preeminence as an MS clinician and thought leader. Dr. Miller graduated from Brandeis University in 1964 and received his medical doctorate from New York University School of Medicine in 1968. Following his residency in neurology at the Albert Einstein College of Medicine, he received additional postdoctoral training in neurovirology and immunology at Albert Einstein College of Medicine, as well as the Johns Hopkins University School of Hygiene and Public Health. During this time, he was the recipient of a fellowship from the National MS Society. In March, 2004, Dr. Miller assumed the position of Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Mount Sinai School of Medicine. For 23 years prior to that, he headed the Division of Neurology at Maimonides Medical Center in Brooklyn, NY where he continues to serve as Co-director of the MS Care Center.
 
Dr. Miller has been the Chief Medical Officer of the National MS Society since October 2001 and served as Chairman of the National Medical Advisory Board of the NMSS from 2001- 2009. He has been a member of the NMSS Board of Directors since 2003. He was Chairman of the Clinical Advisory Committee of the New York Chapter of the NMSS from 1991-2004. He was Chairman of the Professional Education Committee of the NMSS and is a Past President of the Consortium of MS Centers. He was the first Chairman of the Multiple Sclerosis section of the American Academy of Neurology.
 
Dr. Miller is active with the American Academy of Neurology, and is a member of the Board of Directors. He was Editor of Continuum, their bimonthly continuing education publication, from 2003 through 2012, and continues to serve as Editor of Continuum Audio. Dr. Miller has served as the Principal Investigator for many clinical trials in MS and has been a member of many data and safety monitoring boards.

Suhayl Dhib-Jalbut, MD

Suhayl Dhib-Jalbut, MD
Professor and Chairman
Department of Neurology
RUTGERS-Robert Wood Johnson Medical School
Chief, Neurology Science
Robert Wood Johnson University Hospital
New Brunswick, NJ

Dr. Suhayl Dhib-Jalbut is Professor and Chairman of the Department of Neurology at RUTGERS-Robert Wood Johnson Medical School, and Chief of Neurology at the Robert Wood Johnson University Hospital. He is also Director of the RWJ Center for Multiple Sclerosis (MS).

Dr. Dhib-Jalbut graduated Alpha-Omega-Alpha from the American University of Beirut in Lebanon and completed his Neurology training at the University of Cincinnati. He then joined the National Institutes of Health (NIH) in Bethesda, Maryland where he specialized in MS and Neuroimmunology. Dr. Dhib-Jalbut joined the faculty of the University of Maryland in Baltimore in July 1990 where he established a research program in MS before his recruitment to Robert Wood Johnson Medical School in 2003.

Dr. Dhib-Jalbut's research, which has been funded by the NIH, The National MS Society, and Industry, include how MS therapies work, biomarkers of treatment response in MS, and neuroprotective gene therapy. Dr. Dhib-Jalbut published over 100 manuscripts in the scientific literature. He served as Associate Editor for the Journal of Neuroimmunology. He currently serves on the Editorial Boards of JICR and MS International. He served on several National and International scientific committees including Chairmanship of the Scientific Committee for the World Congress on MS in 2008. Dr. Dhib-Jalbut has been on the Best Doctors in America list since 2009 and has received several awards and recognitions. Most recently he was awarded the Norman H. Edelman clinical science mentoring award at RUTGERS, the Medical Excellence Award by the National MS Society NJ Metro Chapter and the Edward Ill Award for Excellence in clinical research in the State of New Jersey. Dr. Dhib-Jalbut currently serves as President of the Americas Committee for Treatment and Research in MS (ACTRIMS).

Bruce Cree, MD, PhD, MCR

Bruce Cree, MD, PhD, MCR
Associate Professor of Clinical Neurology
Clinical Research Director
Multiple Sclerosis Center
University of California, San Francisco
San Francisco, CA

Bruce Cree, MD, PhD, MCR is an Associate Professor of Clinical Neurology in the Department of Neurology at the University of California, San Francisco (UCSF). Dr. Cree completed his medical doctorate and PhD in biochemistry at UCSF. His neurology residency training was at Columbia University. He returned to UCSF for a Sylvia Lawry National Multiple Sclerosis Society fellowship and received a Masters in Clinical Research.

Dr. Cree is the Clinical Research Director at the UCSF MS Center. He divides his time between patient care, clinical research, and teaching. His research focuses on the genetic epidemiology of multiple sclerosis, understanding factors that contribute to disease progression, and developing novel therapies for MS through clinical trials. In addition to multiple sclerosis, Dr. Cree specializes in research and care of patients with neuromyelitis optica and transverse myelitis.
1. Select and initiate effective DMD therapies earlier in the course of MS
2. Develop individualized MS therapies that optimize adherence and improve patient outcomes
3. Incorporate newer MRI measures and emerging biomarkers to enable more accurate diagnosis and monitoring of disease activity in MS

DISCLOSURE POLICY STATEMENT
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
 
All persons in a position to control the content of a continuing medical education program sponsored by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
 
The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.
 
Faculty Disclosures
The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
 
Bruce Cree, MD, PhD, MCR – Consultant: Biogen Idec, EMD Serono, Genzyme, Novartis, Sanofi-Aventis, Teva Neuroscience; Research: Hoffman La Roche
 
Suhayl Dhib-Jalbut, MD – Speaker: Bayer HealthCare, Biogen Idec, EMD Serono, Genzyme, Teva
 
Aaron E. Miller, MD – Consultant: EMD Serono, GlaxoSmithKline, Nuron Biotech, Ono Pharmaceutical, Teva Neuroscience; Consultant/Research: Acorda, Biogen Idec, Genzyme/Sanofi-Aventis, Novartis
 
                                                           
Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Matthew Horn, MD; Blair St. Amand; Jay Katz, MA, CCMEP; Dana Simpler, MD; Joshua Kilbridge: Nothing to disclose
                                                   
 
DISCLOSURE ATTESTATION
 
DISCLAIMER
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
 
CREDIT DESIGNATION
 
Physicians – The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
 
For questions regarding CME credit, the post-test, or evaluation, please email contact@rockpointe-pcme.com.
 
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.0 AMA PRA category 1 credits™. Statement of credit will be available to print from your user history page.
 

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the post-test and activity evaluation.
  • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with a 70% or higher on the post-test to receive credit for this activity.
  • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. "
     
COMMERCIAL SUPPORT

This program is supported through an educational grant from EMD Seronao, Novartis, and Teva Neuroscience.

This continuing medical education activity is jointly sponsored by the Potomac Center for Medical Education and Rockpointe.

COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above		 Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

 

Schedule an event with a Standardized Patient
×